The dysregulated neovascularization observed in blinding diseases was reported to be associated with FGF2-FGFR-STAT3 signaling [58] and, moreover, cidofovir, an antiviral drug targeted for cancers due to human papilloma viral infections, enhanced apoptosis of tumor cells and attenuated FGF2-driven progression of vascular tumors through FGF2-FGFR-mediated Erk42/44 activation in endothelial cells [63]. This evidence concerns the gene FGF2 and neoplasm.